STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] ANI Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) filed a Form 144 proposing the sale of 91,000 common shares. The shares are scheduled for an approximate sale date of 08/15/2025 through Morgan Stanley Smith Barney LLC and carry an aggregate market value of $7,866,267.50. The filing reports 21,688,772 shares outstanding, meaning the proposed sale represents a small fraction of total shares. The 91,000 shares were acquired on 11/19/2021 in exchange for convertible preferred shares and were paid for in cash on the acquisition date. No other sales in the prior three months were reported.

Positive
  • Clear compliance disclosure: The filer provides required Rule 144 details including broker, acquisition date, basis of acquisition, aggregate market value, and approximate sale date.
Negative
  • None.

Insights

TL;DR: Insider plans to sell 91,000 ANIP shares (~$7.87M) acquired via convertible preferreds in 2021; filing follows Rule 144 disclosure requirements.

The Form 144 discloses a proposed sale executed through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/15/2025. The position was originally acquired on 11/19/2021 via convertible preferred shares and paid in cash, which is relevant for determining resale eligibility under Rule 144. The disclosed aggregate market value ($7.87M) and the stated shares outstanding (21,688,772) allow market participants to gauge the sale's relative size; the sale represents a modest percentage of outstanding shares.

TL;DR: The filer provided required attestation and signature language; no undisclosed material information is claimed.

The filing includes the standard attestation that the seller is not aware of any undisclosed material adverse information about the issuer and notes the Rule 10b5-1 trading plan language if applicable. The submission identifies the broker and confirms there were no related sales in the prior three months. From a governance and disclosure standpoint, the filing appears procedurally complete for a Rule 144 notice.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does ANIP's Form 144 disclose about the proposed sale?

The Form 144 discloses a proposed sale of 91,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $7,866,267.50 and approximate sale date of 08/15/2025.

How and when were the 91,000 ANIP shares acquired?

The shares were acquired on 11/19/2021 through a conversion of convertible preferred shares, with payment noted as cash on the acquisition date.

How large is the proposed sale relative to ANIP's outstanding shares?

The filing reports 21,688,772 shares outstanding, so the 91,000-share sale represents a small percentage of total shares outstanding.

Were there any other sales by this person in the past three months?

The Form 144 indicates Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed ANIP sale?

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
Ani Pharmaceutic

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data

1.90B
19.13M
10.42%
97.8%
9.42%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BAUDETTE